Cargando…

A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas

Detalles Bibliográficos
Autores principales: Goswami, Trishna, Canelos, Paola, Parikh, Radhika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288733/
http://dx.doi.org/10.1186/2051-1426-2-S3-P73
_version_ 1782352016078536704
author Goswami, Trishna
Canelos, Paola
Parikh, Radhika
author_facet Goswami, Trishna
Canelos, Paola
Parikh, Radhika
author_sort Goswami, Trishna
collection PubMed
description
format Online
Article
Text
id pubmed-4288733
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42887332015-01-15 A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas Goswami, Trishna Canelos, Paola Parikh, Radhika J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288733/ http://dx.doi.org/10.1186/2051-1426-2-S3-P73 Text en Copyright © 2014 Goswami et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Poster Presentation
Goswami, Trishna
Canelos, Paola
Parikh, Radhika
A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas
title A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas
title_full A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas
title_fullStr A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas
title_full_unstemmed A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas
title_short A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas
title_sort phase ib/ii open-label study to evaluate the safety and efficacy of medi-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive b cell lymphomas
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288733/
http://dx.doi.org/10.1186/2051-1426-2-S3-P73
work_keys_str_mv AT goswamitrishna aphaseibiiopenlabelstudytoevaluatethesafetyandefficacyofmedi551incombinationwithimmunomodulatingtherapyinpatientswithrelapsedorrefractoryaggressivebcelllymphomas
AT canelospaola aphaseibiiopenlabelstudytoevaluatethesafetyandefficacyofmedi551incombinationwithimmunomodulatingtherapyinpatientswithrelapsedorrefractoryaggressivebcelllymphomas
AT parikhradhika aphaseibiiopenlabelstudytoevaluatethesafetyandefficacyofmedi551incombinationwithimmunomodulatingtherapyinpatientswithrelapsedorrefractoryaggressivebcelllymphomas
AT goswamitrishna phaseibiiopenlabelstudytoevaluatethesafetyandefficacyofmedi551incombinationwithimmunomodulatingtherapyinpatientswithrelapsedorrefractoryaggressivebcelllymphomas
AT canelospaola phaseibiiopenlabelstudytoevaluatethesafetyandefficacyofmedi551incombinationwithimmunomodulatingtherapyinpatientswithrelapsedorrefractoryaggressivebcelllymphomas
AT parikhradhika phaseibiiopenlabelstudytoevaluatethesafetyandefficacyofmedi551incombinationwithimmunomodulatingtherapyinpatientswithrelapsedorrefractoryaggressivebcelllymphomas